Anticonvulsant Drug Development (ADD) Program

Research Services • Salt Lake City, Utah, United States • 1-10 Employees

Company overview

Headquarters	30 S 2000 E, Salt Lake City, Utah 84112, US
Phone number	+18001000
Websites	utah.edu pharmacy.utah.edu
NAICS	5417
Keywords	Epilepsy And Neuroscience
Founded	1975
Employees	1-10
Socials

Key Contact at Anticonvulsant Drug Development (ADD) Program

Vanja Panic

Assistant Director (Operations)

About Anticonvulsant Drug Development (ADD) Program

The project uses preclinical seizure models and neuroscience techniques to help develop new antiepileptic agents. Some 800-1000 novel compounds per year are evaluated against conventional drugs for anticonvulsant efficacy and potency, neurotoxicity, effect on liver function, and mechanism of action. Promising compounds, which exhibit a high level and/or unusual spectrum of anticonvulsant activity with superior therapeutic potential, are selected for detailed toxicology studies and subsequent clinical trials in epileptic patients. The project has been continually funded since 1975 and every new anticonvulsant introduced to clinical use in the USA during the past 40 years has been evaluated in this research program. The program is an integral part of the Department of Pharmacology and Toxicology and, as such, provides a site for research training of undergraduate students, departmental graduate students and postdoctoral fellows. Faculty aligned with the program also provide instruction to professional students in the College of Pharmacy and the School of Medicine.

Anticonvulsant Drug Development (ADD) Program revenue & valuation

Annual revenue	$342,220
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Research Services industry and current estimated revenues	$1,100,000
Total funding	No funding

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Director

Funding Data

Anticonvulsant Drug Development (ADD) Program has never raised funding before.

Frequently asked questions

Anticonvulsant Drug Development (ADD) Program is located in Salt Lake City, Utah, US.

You can reach Anticonvulsant Drug Development (ADD) Program at +18001000.

Anticonvulsant Drug Development (ADD) Program was founded in 1975, making it 51 years old. The company has established itself as a significant player in its industry over this time.

Anticonvulsant Drug Development (ADD) Program has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at Anticonvulsant Drug Development (ADD) Program

Vanja Panic

Assistant Director (Operations)

4.8

40,000 users